These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30742665)

  • 1. Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis.
    Parodis I; Ding H; Zickert A; Cosson G; Fathima M; Grönwall C; Mohan C; Gunnarsson I
    PLoS One; 2019; 14(2):e0212068. PubMed ID: 30742665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma sMer, sAxl and GAS6 levels correlate with disease activity and severity in lupus nephritis.
    Gong S; Xu Z; Liu Y; Xing L; Ma J; Yu C; Liu X; Jia X; Xie R; Sui M
    Eur J Clin Invest; 2019 Mar; 49(3):e13064. PubMed ID: 30588607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes in refractory lupus nephritis: Data from an observational study.
    Gururani S; Devarasetti PK; Uppin M; Rajasekhar L
    Lupus; 2021 Oct; 30(11):1725-1731. PubMed ID: 34304627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.
    Parodis I; Ding H; Zickert A; Arnaud L; Larsson A; Svenungsson E; Mohan C; Gunnarsson I
    Scand J Rheumatol; 2017 Jul; 46(4):263-272. PubMed ID: 27973968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-sectional study of plasma Axl, ferritin, IGFBP4 and sTNFR2 as biomarkers of disease activity in childhood-onset SLE: A study of the Pediatric Nephrology Research Consortium.
    Soliman SA; Haque A; Mason S; Greenbaum LA; Hicks MJ; Mohan C; Wenderfer SE
    Lupus; 2021 Aug; 30(9):1394-1404. PubMed ID: 33990158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus.
    Liphaus BL; Lima L; Palmeira P; Silva CA; Goldenstein-Schainberg C; Carneiro-Sampaio M
    Clin Rheumatol; 2020 Feb; 39(2):509-514. PubMed ID: 31655933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort.
    Vandepapelière J; Aydin S; Cosyns JP; Depresseux G; Jadoul M; Houssiau FA
    Lupus; 2014 Feb; 23(2):159-65. PubMed ID: 24300780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology-Renal Pathology Society (ISN-RPS) classification: retrospective observational study.
    Hwang J; Kim HJ; Oh JM; Ahn JK; Lee YS; Lee J; Kim YG; Huh WS; Seo J; Koh EM; Cha HS
    Rheumatol Int; 2012 Jul; 32(7):1877-84. PubMed ID: 21442173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity.
    Zizzo G; Guerrieri J; Dittman LM; Merrill JT; Cohen PL
    Arthritis Res Ther; 2013; 15(6):R212. PubMed ID: 24325951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis.
    Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau FA; Tamirou F
    Rheumatology (Oxford); 2020 Nov; 59(11):3424-3434. PubMed ID: 32353879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the 2018 and 2003 International Society of Nephrology/Renal Pathology Society classification in terms of renal prognosis in patients of lupus nephritis: a retrospective cohort study.
    Umeda R; Ogata S; Hara S; Takahashi K; Inaguma D; Hasegawa M; Yasuoka H; Yuzawa Y; Hayashi H; Tsuboi N
    Arthritis Res Ther; 2020 Nov; 22(1):260. PubMed ID: 33148339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational study of outcome in SLE patients with biopsy-verified glomerulonephritis between 1986 and 2004 in a defined area of southern Sweden: the clinical utility of the ACR renal response criteria and predictors for renal outcome.
    Nived O; Hallengren CS; Alm P; Jönsen A; Sturfelt G; Bengtsson AA
    Scand J Rheumatol; 2013; 42(5):383-9. PubMed ID: 23829689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of childhood lupus nephritis in Saudi children.
    Al-Mayouf SM; AlAmeer A; Alfattani A; Alsonbul A
    Saudi J Kidney Dis Transpl; 2017; 28(5):1015-1020. PubMed ID: 28937057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphological Indexes: Can They Predict Lupus Nephritis Outcomes? A Retrospective Study.
    Navarro D; Ferreira AC; Viana H; Carvalho F; Nolasco F
    Acta Med Port; 2019 Oct; 32(10):635-640. PubMed ID: 31625875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus.
    Mok CC; Ding HH; Kharboutli M; Mohan C
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1303-9. PubMed ID: 26749069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan.
    Nakano M; Kubo K; Shirota Y; Iwasaki Y; Takahashi Y; Igari T; Inaba Y; Takeshima Y; Tateishi S; Yamashita H; Miyazaki M; Sato H; Kanda H; Kaneko H; Ishii T; Fujio K; Tanaka N; Mimori A
    Lupus; 2019 Aug; 28(9):1062-1073. PubMed ID: 31296139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study.
    Chen YM; Hung WT; Liao YW; Hsu CY; Hsieh TY; Chen HH; Hsieh CW; Lin CT; Lai KL; Tang KT; Tseng CW; Huang WN; Chen YH
    Lupus; 2019 Apr; 28(5):658-666. PubMed ID: 30971165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study.
    Karlsson L; Zickert A; Svenungsson E; Schmidt-Mende J; Faustini F; Gunnarsson I
    Clin Rheumatol; 2023 Nov; 42(11):2981-2986. PubMed ID: 37439924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus.
    Ekman C; Jönsen A; Sturfelt G; Bengtsson AA; Dahlbäck B
    Rheumatology (Oxford); 2011 Jun; 50(6):1064-9. PubMed ID: 21278074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AXL receptor tyrosine kinase is increased in patients with heart failure.
    Batlle M; Recarte-Pelz P; Roig E; Castel MA; Cardona M; Farrero M; Ortiz JT; Campos B; Pulgarín MJ; Ramírez J; Pérez-Villa F; García de Frutos P
    Int J Cardiol; 2014 May; 173(3):402-9. PubMed ID: 24681018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.